Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the efficacy of peginterferon beta-1a in
reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis
(RMS) at 1 year. The secondary objectives of this study are to determine whether
peginterferon beta-1a, at 1 year when compared with placebo, is effective in reducing the
total number of new or newly enlarging T2 hyperintense lesions on brain magnetic resonance
imaging (MRI) scans, reducing the proportion of participants who relapse, and slowing the
progression of disability.